A groundbreaking study reveals semaglutide, already known for weight loss and diabetes treatment, is effective for fatty liver disease, benefiting two-thirds of participants in a recent trial. This could revolutionize treatment options!
New research reveals semaglutide, the active ingredient in Wegovy, shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease affecting millions. The study indicates significant improvements in liver health among participants, leading to hopes for FDA approval.